¼¼°èÀÇ ¸é¿ª µ¶¼Ò ½ÃÀå : À¯Çüº°, Àü´Þ ¹æ¹ýº°, ÀûÀÀÁõº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Immunotoxins Market, By Type, By Delivery Method, By Target Indication, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1584131
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 303 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,702,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,728,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 8,174,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸é¿ª µ¶¼Ò ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 4,290¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 8.90%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸é¿ª µ¶¼Ò ½ÃÀå - ½ÃÀå ¿ªÇÐ

¾ÏÁ¨°ú Á¨Á¨°ú °°Àº ´ëÇü Á¦¾à»çµéÀº ¸Å³â ¼ö½Ê¾ï ´Þ·¯¸¦ Ç¥Àû ¾Ï Ä¡·áÁ¦ °³¹ß¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ¿¬±¸ ÅõÀÚ¿Í Àü·«Àû ÆÄÆ®³Ê½Ê Áõ°¡´Â ¸é¿ªµ¶¼Ò ½ÃÀåÀÇ Çõ½ÅÀ» Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò¿¡ µû¸£¸é 2021³â ¹Ì±¹¿¡¼­ ¾à 190¸¸ ¸íÀÌ »õ·Î ¾Ï Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÌ ½Ã±ÞÇÏ´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù. ¾Æ½ºÆ®¶óÁ¦³×Ä«¿Í ¸ÓÅ©°¡ Çù·ÂÇÏ¿© Ç×ü ¾à¹° º¹ÇÕü ±â¼úÀ» ¹ßÀü½ÃŰ´Â °Í°ú °°Àº Çù·Â °ü°è´Â Ä¡·á È¿°ú¸¦ ³ôÀÌ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, À¯·´¿¬ÇÕ(EU)ÀÇ Horizon 2020 ÇÁ·Î±×·¥Àº ¸é¿ªµ¶¼Ò¿¡ ÃÊÁ¡À» ¸ÂÃá ¼ö¸¹Àº ¿¬±¸ ÀÌ´Ï¼ÅÆ¼ºê¿¡ ÀÚ±ÝÀ» Áö¿øÇÏ¿© ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °øµ¿¿¬±¸°¡ Ȱ¹ßÇØÁü¿¡ µû¶ó ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí Ä¡·á ¿É¼ÇÀ» ³ÐÈú ¼ö ÀÖ´Â »õ·Î¿î ¸é¿ªµ¶¼Ò¸¦ °³¹ßÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¸é¿ªµ¶¼Ò ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®ÀÇ ºÐ¼®¿¡ µû¸£¸é, ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032³â) µ¿¾È ¿¬Æò±Õ ¾à 8.90%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¸Å³â ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯Çüº°·Î´Â ´ÜŬ·Ð Ç×ü ±â¹Ý ¸é¿ªµ¶¼Ò°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àü´Þ ¹æ¹ýº°·Î´Â 2023³â¿¡´Â Àü½Å Åõ¿©°¡ ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

ÀûÀÀÁõº°·Î´Â Ç÷¾×¾ÏÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâ 1À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

¸é¿ªµ¶¼Ò ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è ¸é¿ª µ¶¼Ò ½ÃÀåÀº À¯Çü, Àü´Þ ¹æ¹ý, ÀûÀÀÁõ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº À¯Çü¿¡ µû¶ó ÀçÁ¶ÇÕ ¸é¿ªµ¶¼Ò, Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) T ¼¼Æ÷ Ä¡·á, ´ÜÀÏ Å¬·Ð Ç×ü ±â¹Ý µî ¼¼ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. ´ÜÀÏŬ·ÐÇ×ü ±â¹Ý ¸é¿ªµ¶¼Ò´Â Ç¥ÀûÄ¡·á¿¡ ´ëÇÑ È¿´ÉÀÌ ÀÔÁõµÇ¾î ½ÃÀå Á¡À¯À²ÀÌ °¡Àå ³ôÀ¸¸ç, Çõ½ÅÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ´Â ÀçÁ¶ÇÕ ¸é¿ªµ¶¼Ò°¡ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) T ¼¼Æ÷ Ä¡·á´Â Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ¸ç 3À§¸¦ Â÷ÁöÇß½À´Ï´Ù.

Àü´Þ ¹æ½Ä¿¡ µû¶ó Àü½Å Åõ¿©¿Í ±¹¼Ò Åõ¿©ÀÇ µÎ °¡Áö ¹üÁÖ·Î ³ª´¹´Ï´Ù. Àü½Å Åõ¿©´Â ±¤¹üÀ§ÇÑ ¾ÏÀ» È¿°úÀûÀ¸·Î Ä¡·áÇÒ ¼ö ÀÖ´Ù´Â Á¡¿¡¼­ ¿ì¼±¼øÀ§°¡ ³ôÀ¸¸ç, ±¹¼Ò Åõ¿©´Â ºÎÀÛ¿ëÀÌ ÀûÀº Ç¥Àû Ä¡·á¸¦ Á¦°øÇÑ´Ù´Â Á¡¿¡¼­ ±× µÚ¸¦ ÀÕ½À´Ï´Ù. µÎ °¡Áö ¹æ¹ý ¸ðµÎ ´Ù¾çÇÑ Ä¡·á ¿ä±¸¿Í ȯÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ´ëÀÀÇÏ¿© Ä¡·á ¿É¼ÇÀ» È®ÀåÇÕ´Ï´Ù.

¸é¿ªµ¶¼Ò ½ÃÀå - Áö¸®Àû ÅëÂû·Â

¸é¿ªµ¶¼Ò ½ÃÀåÀÇ Áö¿ªÀû »óȲÀ» »ìÆìº¸¸é ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ Å« ¿òÁ÷ÀÓÀÌ ÀÖÀ¸¸ç, °¢ Áö¿ªÀÌ ½ÃÀå ¿ªÇп¡ °íÀ¯ÇÑ ±â¿©¸¦ Çϰí ÀÖÀ½À» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ºÏ¹Ì, ƯÈ÷ ¹Ì±¹Àº ÷´Ü ÀÇ·á ÀÎÇÁ¶ó, ¿¬±¸°³¹ß¿¡ ´ëÇÑ ³ôÀº ÅõÀÚ, ¾ÏÁ¨°ú Á¨Á¨°ú °°Àº ´ëÇü Á¦¾àȸ»çÀÇ Á¸Àç·Î ÀÎÇØ ½ÃÀå Á¡À¯À²À» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³¾Ï¿¬±¸¼Ò(National Cancer Institute)´Â ÀÌ Áö¿ª¿¡¼­ ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè°ú ±â¼ú Çõ½ÅÀ» º¸¿©ÁÖ´Â °­·ÂÇÑ ¸é¿ªµ¶¼ÒÄ¡·áÁ¦ ÆÄÀÌÇÁ¶óÀÎÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. À¯·´µµ ÁÖ¿ä ½ÃÀåÀ¸·Î, µ¶Àϰú ¿µ±¹ µî ¼±Áø Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿ø°ú µ¶ÀÏ, ¿µ±¹ µî ¿©·¯ ±¹°¡¿¡¼­ Á¤¹ÐÀÇ·áÀÇ ¹ßÀüÀÌ µÎµå·¯Áö¸é¼­ Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¾Ï ¹ßº´·ü Áõ°¡¿Í ÀÇ·á Á¢±Ù¼º È®´ë¿¡ ÈûÀÔ¾î À¯¸ÁÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Áß±¹À̳ª Àεµ¿Í °°ÀÌ Á¤ºÎ°¡ »ý¸í°øÇÐ ¿¬±¸¿¡ ÅõÀÚÇϰí ÀÖ´Â ±¹°¡¿¡¼­´Â ´õ¿í ±×·¯ÇÕ´Ï´Ù. ÇöÁö ±â¾÷°ú ±¹Á¦ ±â¾÷°úÀÇ Çù·Â °ü°è´Â ÀÌ Áö¿ª ½ÃÀå ÀáÀç·ÂÀ» ´õ¿í Çâ»ó½ÃŰ°í ¸é¿ª µ¶¼Ò Ä¡·áÀÇ ¼¼°è ¹ßÀü¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¸é¿ªµ¶¼Ò ½ÃÀå - °æÀï ±¸µµ:

¸é¿ªµ¶¼Ò ½ÃÀå °æÀï ±¸µµ´Â ±âÁ¸ Á¦¾à»ç¿Í Çõ½ÅÀû ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷ÀÌ È¥ÀçµÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¸ðµÎ ¿¬±¸°³¹ß°ú Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ½ÃÀå Á¡À¯À²À» ³õ°í °æÀïÇϰí ÀÖ½À´Ï´Ù. ¾ÏÁ¨, Á¦³ÙÅØ, À϶óÀÌ ¸±¸® µî ÁÖ¿ä ±â¾÷µéÀº ¾Ï ºÐ¾ß¿¡¼­ÀÇ Ç³ºÎÇÑ ÀÚ¿ø°ú Àü¹®¼ºÀ» ¹ÙÅÁÀ¸·Î ¸é¿ªµ¶¼Ò Ä¡·áÁ¦ÀÇ °³¹ß ¹× »ó¿ëÈ­¿¡ Àû±Ø ³ª¼­°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¾ÏÁ¨ÀÌ ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÇ ½ÂÀÎÀ» ¹ÞÀº ¸é¿ªµ¶¼ÒÁ¦Á¦ ºê¸®³ªÅõ¸ð¸¿(Blincyto)Àº ƯÁ¤ ¹éÇ÷º´ Ä¡·á¿¡ ÀÖ¾î º¥Ä¡¸¶Å· ´ë»óÀÌ µÇ°í ÀÖÀ¸¸ç, ÀÌ Ä¡·á¹ýÀÇ ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. À̹³ëÁ¨(Immunogen)°ú ½ºÅ۽óÊÁö Å×¶óǻƽ½º(Stem Synergy Therapeutics)¿Í °°Àº ½Å»ý ±â¾÷µéµµ µ¶Æ¯ÇÑ ¸é¿ªµ¶¼Ò Èĺ¸¹°Áú°ú »õ·Î¿î Àü´Þ ¸ÞÄ¿´ÏÁòÀ» °³¹ßÇÏ¿© Çõ½Å°ú °æÀï ¾Ð·ÂÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀå¿¡¼­´Â °øµ¿¿¬±¸°¡ ÀϹÝÀûÀ̸ç, ¿¹¸¦ µé¾î, »ý¸í°øÇÐ ±â¾÷°ú Çмú ±â°ü°úÀÇ Á¦ÈÞ´Â ¿¬±¸ ³ë·ÂÀ» ÃËÁøÇÏ°í ¸é¿ªµ¶¼ÒÀÇ »õ·Î¿î ÀÀ¿ë ¹× Á¶ÇÕÀ» ¸ð»öÇÏ´Â ÀÓ»ó½ÃÇèÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªµ¿ÀûÀΠȯ°æÀº »ý¸í°øÇÐ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿Í °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ¸é¿ªµ¶¼Ò ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀå°ú ¹ßÀüÀ» ÀÌ·ê °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¸é¿ª µ¶¼Ò ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¸é¿ª µ¶¼Ò ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå ¸é¿ª µ¶¼Ò »ê¾÷ Á¶»ç

Á¦5Àå ¸é¿ª µ¶¼Ò ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå ¸é¿ª µ¶¼Ò ½ÃÀå ±¸µµ

Á¦7Àå ¸é¿ª µ¶¼Ò ½ÃÀå - À¯Çüº°

Á¦8Àå ¸é¿ª µ¶¼Ò ½ÃÀå - Àü´Þ ¹æ¹ýº°

Á¦9Àå ¸é¿ª µ¶¼Ò ½ÃÀå - ÀûÀÀÁõº°

Á¦10Àå ¸é¿ª µ¶¼Ò ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦11Àå ¸é¿ª µ¶¼Ò ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - ¸é¿ª µ¶¼Ò ¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Immunotoxins Market size was valued at USD 142.90 Million in 2023, expanding at a CAGR of 8.90% from 2024 to 2032.

The Immunotoxins market, which focuses on targeted therapies combining antibodies with cytotoxic agents to selectively kill cancer cells, is gaining momentum due to the increasing prevalence of cancer and autoimmune diseases. With an estimated 1.9 million new cancer cases expected in the U.S. alone in 2024, the demand for effective treatments is on the rise. This growing need is spurred by advancements in biotechnology, leading to the development of more effective immunotoxin formulations that enhance therapeutic efficacy while minimizing side effects. However, challenges such as high production costs and stringent regulatory approvals can hinder market growth. Moreover, the complexity of immunotoxin mechanisms can lead to variability in patient responses, raising concerns about treatment consistency. Nevertheless, the expanding research pipeline and the exploration of combination therapies present significant opportunities for market expansion. Companies are increasingly investing in clinical trials and strategic collaborations to innovate and diversify their product offerings, positioning themselves to meet the evolving needs of patients and healthcare providers in the oncology landscape.

Immunotoxins Market- Market Dynamics

Increasing Investment in Research and Strategic Partnerships Fuels Innovation in the Film Capacitor Market

The increasing investment in research and strategic partnerships is significantly driving innovation in the immunotoxins market, with major pharmaceutical companies like Amgen and Genentech allocating billions annually to develop targeted cancer therapies. According to the National Cancer Institute, approximately 1.9 million new cancer cases were diagnosed in the U.S. in 2021, underscoring the urgent need for innovative treatments. Collaborations such as the partnership between AstraZeneca and Merck to advance antibody-drug conjugate technology are pivotal in enhancing therapeutic efficacy. Moreover, the European Union's Horizon 2020 program has funded numerous research initiatives focusing on immunotoxins, further solidifying the sector's growth. As these collaborations continue to flourish, they are expected to lead to the development of novel immunotoxins that improve patient outcomes and expand treatment options.

Immunotoxins Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.90% over the forecast period (2024-2032)

Based on Type segmentation, Monoclonal Antibody-Based Immunotoxins were predicted to show maximum market share in the year 2023

Based on Delivery Method segmentation, Systemic Administration was the leading type in 2023

Based on Target Indication segmentation, Hematologic Malignancies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Immunotoxins Market- Segmentation Analysis:

The Global Immunotoxins Market is segmented on the basis of Type, Delivery Method, Target Indication, End-User, and Region.

The market is divided into three categories based on Type: Recombinant Immunotoxins, Chimeric Antigen Receptor (CAR) T-cell therapy, and Monoclonal Antibody-Based Immunotoxins. Monoclonal Antibody-Based Immunotoxins hold the highest market share due to their established efficacy in targeted therapies, followed by Recombinant Immunotoxins, which offer innovative treatment options. Chimeric Antigen Receptor (CAR) T-cell therapy ranks third, showcasing significant potential.

The market is divided into two categories based on the Delivery Method: Systemic Administration and Local Administration. Systemic Administration is prioritized due to its ability to treat widespread cancers effectively, while Local Administration follows, offering targeted treatment with fewer side effects. Both methods cater to different therapeutic needs and patient profiles, enhancing treatment options.

Immunotoxins Market- Geographical Insights

The geographical landscape of the Immunotoxins market reveals significant activity across North America, Europe, and Asia-Pacific, each contributing uniquely to market dynamics. North America, particularly the United States, leads in market share due to advanced healthcare infrastructure, high investment in research and development, and the presence of major pharmaceutical companies like Amgen and Genentech. The National Cancer Institute has highlighted a robust pipeline of immunotoxin therapies, indicating ongoing clinical trials and innovations in this region. Europe is also a key player, driven by regulatory support for advanced therapies and a growing emphasis on precision medicine, with notable developments in countries like Germany and the UK. Meanwhile, the Asia-Pacific region is emerging as a promising market, fueled by increasing cancer prevalence and expanding healthcare access, particularly in countries like China and India, where governments are investing in biotechnology research. Collaborative efforts between local firms and international companies further enhance the market potential in this region, contributing to the global advancement of immunotoxin therapies.

Immunotoxins Market- Competitive Landscape:

The competitive landscape of the Immunotoxins market is characterized by a mix of established pharmaceutical companies and innovative biotech firms, all vying for market share through research, development, and strategic collaborations. Major players such as Amgen, Genentech, and Eli Lilly are actively involved in developing and commercializing immunotoxin therapies, leveraging their extensive resources and expertise in oncology. For instance, Amgen's FDA-approved immunotoxin, blinatumomab (Blincyto), has set a benchmark in treating certain types of leukemia, illustrating the potential of this therapeutic approach. Emerging players, like ImmunoGen and StemSynergy Therapeutics, are also making strides with unique immunotoxin candidates and novel delivery mechanisms, fostering innovation and competitive pressure. Collaborations are common in this market; for example, partnerships between biotech firms and academic institutions are driving research efforts, leading to clinical trials that explore new applications and combinations of immunotoxins. This dynamic environment is further supported by increasing investments in biotechnology research and an emphasis on personalized medicine, positioning the Immunotoxins market for continued growth and advancement.

Recent Developments:

In April 2024, Invera Inc. and Astellas Pharma announced a collaboration to develop therapeutic bispecific antibodies. Astellas Pharma will utilize Invera's B-Body bispecific antibody platform to advance its research in bispecific therapeutic applications.

In January 2023, List Biological Labs, Inc. enhanced its bacterial therapeutic manufacturing capabilities by incorporating a new 500L bioreactor along with a tangential flow filtration system, aimed at increasing production efficiency and meeting growing demand for bacterial therapeutics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL IMMUNOTOXINS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL IMMUNOTOXINS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMMUNOTOXINS MARKET, BY DELIVERY METHOD- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMMUNOTOXINS MARKET, BY TARGET INDICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMMUNOTOXINS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

GLOBAL IMMUNOTOXINS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Immunotoxins Market Overview

2. Executive Summary

3. Immunotoxins Key Market Trends

4. Immunotoxins Industry Study

5. Immunotoxins Market: COVID-19 Impact Analysis

6. Immunotoxins Market Landscape

7. Immunotoxins Market - By Type

8. Immunotoxins Market - By Delivery Method

9. Immunotoxins Market - By Target Indication

10. Immunotoxins Market - By End-User

11. Immunotoxins Market- By Geography

12. Key Vendor Analysis- Immunotoxins Industry

13. 360 Degree Analyst View

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â